Canaan Partners
http://www.canaan.com/homeCanaan Partners is a venture capital firm that invests in early stage technology and healthcare companies. Since its founding in 1987, Canaan has invested in more than 250 companies including DoubleClick and Match.com.
View Older Stories View More Recent Stories
-
Form 13F-HR Canaan Partners X LLC For: Jun 30
-
Form 13F-HR Canaan Partners XI LLC For: Jun 30
-
World View Names New Chief Financial Officer and Appoints New Member to Its Board of Directors
-
CircleUp Acquired by Brightflow AI
-
Brightflow AI Acquires CircleUp to Deepen Customer Insights and Help Small Businesses Grow
-
OncoResponse Awarded $13 Million in Funding from CPRIT and Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy
-
Lev Announces the Launch of Lev Match
-
Antiva Biosciences Closes $53 Million Series E Equity Financing Led by MPM-BioImpact Capital and Names Kristine Ball President and CEO
-
OncoResponse Presents at AACR 2023 Annual Meeting Preclinical Data Highlighting Dual Antagonist Antibodies Targeting both LILRB1 and LILRB2
-
Relievant Medsystems Raises $50 Million to Advance the Treatment for Chronic Vertebrogenic Low Back Pain
-
Relievant Medsystems Raises $50 Million to Advance the Treatment for Chronic Vertebrogenic Low Back Pain
-
Pathios Therapeutics Unveils PTT-4256, a Highly Potent and Selective Inhibitor of GPR65, in Presentation at American Association for Cancer Research (AACR) Annual Meeting 2023
-
Researchers Report Clinical Proof-of-Concept Data for Vivace Therapeutics' VT3989, a First for a Cancer Drug Targeting the Hippo Pathway, in Oral Presentation at AACR 2023
-
Form 13F-HR Canaan Partners XI LLC For: Mar 31
-
Form 13F-HR Canaan Partners X LLC For: Mar 31
-
ThirtyFiveBio Emerges From Stealth with Presentation of First Data from GPR35 Antagonist Program at American Association for Cancer Research (AACR) Annual Meeting 2023
-
OncoResponse Announces Presentation of Preclinical Data on Dual Antibodies Targeting LILRB1 and LILRB2 at American Association for Cancer Research Annual Meeting 2023 (AACR 2023)
-
Vivace Therapeutics to Unveil First Clinical Data for a Cancer Drug Targeting the Hippo Pathway
-
Halda Therapeutics unveils its first pipeline data for RIPTAC™ therapeutics, a new drug modality, at ASCO GU Symposium
-
Form 13F-HR Canaan Partners X LLC For: Dec 31
-
Form 13F-HR Canaan Partners IX LLC For: Sep 30
-
Form 13F-HR Canaan Partners XI LLC For: Dec 31
-
Appsmith Launches Partner Program to Empower Businesses to Build Business Critical Applications
-
Komprise Raises $37M to Fuel Growth and Advance Leadership in Unstructured Data Management
-
Kraken Appoints Dan Ciporin to Board of Directors
-
OncoResponse to Present at 41st Annual J.P. Morgan Healthcare Conference
-
neonVest Closes Seed Round Led by 7BC Venture Capital for Their SaaS-Based Startup Scaling Platform
-
Lynne Laube, Founder and Former CEO of Cardlytics, Joins Valor Ventures as Operating Partner
-
Pathios Therapeutics Appoints Jeanmarie Guenot, Ph.D., as Non-Executive Director
-
OncoResponse Announces Preclinical Data Highlighting OR2805 Discovery from Elite Responder Platform and OR502 anti-LILRB2 Antibody at SITC 2022
-
Fineqia Sees 7x Uplift in Investment Value in IDEO CoLab Ventures Fund I; No Exposure to FTX
-
Pathios Therapeutics to Present Preclinical Data Highlighting Potential of GPR65 Inhibition as a Powerful Anti-Tumor Immunotherapy Strategy at SITC 2022
-
Amid Rapid Growth, Lev Announces a Wave of Executive Hires, Appointing a Vice President of Marketing, Vice President of Product and Head of People
-
Form 13F-HR Canaan Partners X LLC For: Sep 30
-
Form 13F-HR Canaan Partners XI LLC For: Sep 30
-
OncoResponse Announces Clinical Supply Agreement with Regeneron to Evaluate OR2805 in Combination with Libtayo® (cemiplimab) in Patients with Advanced Cancer
-
Lily AI Closes $25M Series B to Bring the Language of the Customer Across the Entire Retail Value Chain
-
$16.7 Million Cash Out Refinance Loan Secured by Lev Brokers for TIR Equities in Birmingham, Michigan
-
Lev Secures $41.5 Million in Cannabis CRE Financing Across the U.S., Breaking Down Barriers to Federal Loans in the Market
-
Form 13F-HR Canaan Partners XI LLC For: Jun 30
-
Form 13F-HR Canaan Partners X LLC For: Jun 30
-
Form 13F-HR Canaan Partners IX LLC For: Jun 30
-
Lev Brokers Secure $2.3 Million Loan for Durham, NC Townhomes
-
$17.5 Million Construction-to-Permanent Financing Secured by Lev Brokers in Chesterfield, Michigan
-
Hank Debuts Platform to Connect Adults 55+ with In-Person Experiences and Community
-
Aziyo Biologics (AZYO) Appoints Dr. C. Randal Mills as Interim President and CEO
-
Aziyo Biologics Appoints Dr. C. Randal Mills as Interim President and CEO
-
Lev Brokers Secure $11.7 Million Bridge Refinance Deal for Houston Multifamily Apartment Complex
-
Edge Impulse Announces Appointment of Simon Segars to Board of Directors
-
Jina AI Shapes Future of Search as CB Insights Names it in 100 Most Innovative AI Startups for Second Year Running

